Generated by AI
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cell and gene therapies for serious rare diseases. Its current portfolio centers on ZEVASKYN, an autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa, alongside a pipeline of adeno-associated virus-based programs for ophthalmic and other genetic disorders. The company also develops engineered T-cell and viral vector technologies designed to address high-unmet-need conditions in oncology and rare disease settings. Abeona Therapeutics operates from Cleveland, Ohio, with a fully integrated cGMP manufacturing facility that supports commercial production and clinical development activities. The company serves the biotechnology and advanced therapies market, where it plays a specialized role in translating genetic medicine into targeted treatments for patients with limited therapeutic options.
Website6555 Carnegie Avenue
Cleveland, OH, 44103
United States
The latest articles about ABEO.
Abeona Therapeutics is back in focus after analysts cut their fair value estimate from about US$20.64 to roughly US$15.56, which meaningfully reshapes the implied upside in current models. This reset lines up with recent commentary that balances long term optimism around Zevaskyn with concern about slower commercial progress and the effect of dilution on the stock. As you read on, you will see how these price target moves fit into the broader Abeona Therapeutics story and what to watch as the...
Summary of Nov 13's posts. Generated by AI.
Summary of Nov 10's posts. Generated by AI.
Summary of Mar 27's posts. Generated by AI.
Summary of Nov 10's posts. Generated by AI.
Investors talking about ABEO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.